OBJECTIVES: To assess whether serum 25-hydroxyvitamin D (25(OH)D) concentrations relate to transitions between the states of robustness, prefrailty, and frailty and to mortality in older adults. DESIGN: The Invecchiare in Chianti (InCHIANTI) Study, a prospective cohort study. SETTING: Tuscany, Italy. PARTICIPANTS: Adults aged 65 and older (N = 1,155). MEASUREMENTS: Serum 25(OH)D concentrations measured at baseline; frailty state (robust, prefrail, frail) assessed at baseline and 3 and 6 years after enrollment; and vital status determined 3 and 6 years after enrollment. RESULTS: The median (interquartile range) 25(OH)D concentration was 16.0 ng/mL (10.4-25.6 ng/mL; multiply by 2.496 to convert to nmol/L). Prefrail participants with 25(OH)D levels less than 20 ng/mL were 8.9% (95% confidence interval (CI) = 2.5-15.2%) more likely to die, 3.0% (95% CI = -5.6-14.6%) more likely to become frail, and 7.7% (95% CI = -3.5-18.7%) less likely to become robust than prefrail participants with 25(OH)D levels of 20 ng/mL or more. In prefrail participants, each 5-ng/mL decrement of continuous 25(OH)D was associated with 1.46 times higher odds of dying (95% CI = 1.18-2.07) and 1.13 higher odds of incident frailty (95% CI = 0.90-1.39) than with recovery of robustness. Transitions from robustness or frailty were not associated with 25(OH)D levels. CONCLUSION: Results provide evidence that prefrailty is an "at risk" state from which older adults with high 25(OH)D levels are more likely to recover than to decline, but high 25(OH)D levels were not associated with recovery from frailty. Thus, 25(OH)D levels should be investigated as a potential therapy to treat prefrailty and prevent further decline.
OBJECTIVES: To assess whether serum 25-hydroxyvitamin D (25(OH)D) concentrations relate to transitions between the states of robustness, prefrailty, and frailty and to mortality in older adults. DESIGN: The Invecchiare in Chianti (InCHIANTI) Study, a prospective cohort study. SETTING: Tuscany, Italy. PARTICIPANTS: Adults aged 65 and older (N = 1,155). MEASUREMENTS: Serum 25(OH)D concentrations measured at baseline; frailty state (robust, prefrail, frail) assessed at baseline and 3 and 6 years after enrollment; and vital status determined 3 and 6 years after enrollment. RESULTS: The median (interquartile range) 25(OH)D concentration was 16.0 ng/mL (10.4-25.6 ng/mL; multiply by 2.496 to convert to nmol/L). Prefrail participants with 25(OH)D levels less than 20 ng/mL were 8.9% (95% confidence interval (CI) = 2.5-15.2%) more likely to die, 3.0% (95% CI = -5.6-14.6%) more likely to become frail, and 7.7% (95% CI = -3.5-18.7%) less likely to become robust than prefrail participants with 25(OH)D levels of 20 ng/mL or more. In prefrail participants, each 5-ng/mL decrement of continuous 25(OH)D was associated with 1.46 times higher odds of dying (95% CI = 1.18-2.07) and 1.13 higher odds of incident frailty (95% CI = 0.90-1.39) than with recovery of robustness. Transitions from robustness or frailty were not associated with 25(OH)D levels. CONCLUSION: Results provide evidence that prefrailty is an "at risk" state from which older adults with high 25(OH)D levels are more likely to recover than to decline, but high 25(OH)D levels were not associated with recovery from frailty. Thus, 25(OH)D levels should be investigated as a potential therapy to treat prefrailty and prevent further decline.
Authors: Marieke B Snijder; Natasja M van Schoor; Saskia M F Pluijm; Rob M van Dam; Marjolein Visser; Paul Lips Journal: J Clin Endocrinol Metab Date: 2006-05-09 Impact factor: 5.958
Authors: Martine T E Puts; Marjolein Visser; Jos W R Twisk; Dorly J H Deeg; Paul Lips Journal: Clin Endocrinol (Oxf) Date: 2005-10 Impact factor: 3.478
Authors: Karen Bandeen-Roche; Qian-Li Xue; Luigi Ferrucci; Jeremy Walston; Jack M Guralnik; Paulo Chaves; Scott L Zeger; Linda P Fried Journal: J Gerontol A Biol Sci Med Sci Date: 2006-03 Impact factor: 6.053
Authors: Heike A Bischoff-Ferrari; Walter C Willett; John B Wong; Edward Giovannucci; Thomas Dietrich; Bess Dawson-Hughes Journal: JAMA Date: 2005-05-11 Impact factor: 56.272
Authors: M Bonnefoy; G Berrut; B Lesourd; M Ferry; T Gilbert; O Guérin; O Hanon; C Jeandel; E Paillaud; A Raynaud-Simon; G Ruault; Y Rolland Journal: J Nutr Health Aging Date: 2015-03 Impact factor: 4.075
Authors: Brian Buta; Parichoy Pal Choudhury; Qian-Li Xue; Paulo Chaves; Karen Bandeen-Roche; Michelle Shardell; Richard D Semba; Jeremy Walston; Erin D Michos; Lawrence J Appel; Mara McAdams-DeMarco; Alden Gross; Sevil Yasar; Luigi Ferrucci; Linda P Fried; Rita Rastogi Kalyani Journal: J Am Geriatr Soc Date: 2016-12-23 Impact factor: 5.562
Authors: Michelle Shardell; Richard D Semba; Rita R Kalyani; Gregory E Hicks; Stefania Bandinelli; Luigi Ferrucci Journal: J Gerontol A Biol Sci Med Sci Date: 2015-03-07 Impact factor: 6.053
Authors: Sameera A Talegawkar; Stefania Bandinelli; Karen Bandeen-Roche; Ping Chen; Yuri Milaneschi; Toshiko Tanaka; Richard D Semba; Jack M Guralnik; Luigi Ferrucci Journal: J Nutr Date: 2012-10-24 Impact factor: 4.798